ArticleFrontiers of medicine2019

Minimal residual disease-directed immunotherapy for high-risk myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.

Xiaodong Mo et al.PubMed ↗Publisher ↗

No numbers read from the abstract.